Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $3,550,000 — Improvements in vaccines against influenza that increase potency, breadth and durability of protection would improve worldwide ability to combat seasonal influenza as well as emergence of new pandemic influenza viruses. Influenza vaccines have the potential to reduce the risk of symptomatic infectio…
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,680,146 — Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldwide. Intradermal (ID) vaccination with BCG has variable efficacy against pulmonary tuberculosis, the major cause of mortality and disease transmission. We showed that the route and dose of BCG vaccination alters circ…
Arya Biragyn · NATIONAL INSTITUTE ON AGING · 2024 · $360,948 — According to the prevailing Amyloid cascade hypothesis, Alzheimers disease (AD) is caused by decades-long deposition of neurotoxic amyloid Ab-peptide aggregates (Ab plaques) in the brain. It leads to a chain of pathological events, including tauopathy, astrogliosis, accumulation of disease associate…
PHILIP Louis FELGNER · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $1,775,381 — Project Summary/Abstract – Administrative Core We are proposing the creation of the UC Irvine Vaccines for Pandemic Preparedness Center (VPPC), a consortium that will conduct basic and translational research to develop vaccines against prototype members of the Bunyavirus, Paramyxovirus and Picornavi…
Mathias Lichterfeld · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2024 · $149,559 — Project Summary/Abstract, Immune Control (Project 4) Finding a cure for HIV-1 infection is of particular importance for the growing number of HIV-1-infected infants, children and teenagers who will have to take lifelong antiretroviral therapy if curative treatment options will not be available. Rece…
MARGIE CLAPPER · RESEARCH INST OF FOX CHASE CAN CTR · 2024 · $921,373 — Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While…
WENDELL BERES · DUKE UNIVERSITY · 2024 · $595,226 — Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV an…
Timothy R Fouts · ADVANCED BIOSCIENCE LABORATORIES, INC. · 2024 · $1,863,405 — Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV an…
AARON ESSER-KAHN · UNIVERSITY OF CHICAGO · 2024 · $1,989,733 — The offeror proposes to discover adjuvants with two sets of unique properties – (1) directing T cell fates and (2) improving the response to mRNA vaccines. This will be accomplished by screening novel immune-potentiators that direct the innate immune response of the original vaccine or adjuvant to i…
Marc Ladanyi · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $436,396 — RP3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma ABSTRACT Synovial sarcoma (SS) is driven by SS18::SSX-dependent chromatin dysregulation, suggesting that elucidating key aspects of this deregulation might point to therapeutic epigenetic vulnerabilities.…
Edward M. Schwarz · UNIVERSITY OF ROCHESTER · 2024 · $267,775 — Abstract Osteomyelitis is the bane of orthopaedic surgery, of which the majority is caused by Staphylococcus aureus. Prior to this P50 Center of Research Translation on the Osteoimmunology of Bone Infection (CoRTOBI), it was known that these rare infections following elective surgery (~1%), and our …
MORIYA TSUJI · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $1,089,350 — The goal of this contract project is to develop the glycolipid-based adjuvant for human use, with initial indications for a malaria vaccine. The scope of our product development project is to develop our novel CD1d-binding natural killer T (NKT) cell-stimulatory glycolipid, called 7DW8-5, as a versa…
Neil King · UNIVERSITY OF WASHINGTON · 2024 · $2,913,088 — PROJECT SUMMARY – PROJECT 5: mRNA AND mRNA-LAUNCHED NANOPARTICLE VACCINES The goal of Project 5 is to develop generalizable approaches and platforms to design, make, and evaluate mRNA-based vaccines for paramyxovirus, arenavirus, and phenuivirus antigens. We will leverage the industry experience of …
Rafi Ahmed · EMORY UNIVERSITY · 2024 · $673,340 — Our long-term goal is to understand the cellular and molecular basis of immunological memory in humans. We will address this important question in Project 1 by doing a detailed analysis of both humoral and cellular immunity in a longitudinal cohort of over > 700 COVID-19 patients that we have been f…
Scott C Weaver · WASHINGTON UNIVERSITY · 2024 · $3,960,456 — SUMMARY, Project 4 Alphaviruses regularly threaten global health, including long-established emerging viruses like Venezuelan equine encephalitis virus (VEEV, the most important of the encephalitic alphaviruses) and chikungunya virus (CHIKV, the most important arthritogenic alphaviruses) that unexpe…
Deborah H. Fuller · NORTHERN ARIZONA UNIVERSITY · 2024 · $363,131 — SUMMARY Coccidioidomycosis, also known as Valley Fever (VF) impacts residents in arid regions of the world including southwestern US, areas in South and Central America and in Mexico. Annual incidences are rising overall with estimated increases in recent years of more than 200% in some areas. In ad…
RUTH R MONTGOMERY · YALE UNIVERSITY · 2024 · $882,224 — Abstract We propose single-cell technologies to quantify multiparameter immune markers that provide in- depth single-cell data for analysis of immune responses to vaccination in our study cohorts. The shared platforms in this service core provide efficient and reproducible profiling in support of ou…
Steven Bradfute · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $1,758,323 — In Project 2 (P2) we will use cutting-edge antigen engineering to refine vaccine antigen design strategies through iterative assessments of immunogenicity and protective efficacy to generate optimized vaccine immunogens against nairo-, hanta-, and paramyxoviruses. Our approach will establish a prote…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $236,999 — The elicitation of cross-neutralizing or broadly neutralizing Abs (bNAbs) to diverse HIV strains by Env vaccination remains a high priority for a broadly efficacious vaccine. The elicitation of bNAbs against conserved Env determinants remains elusive; however, the recent isolation of bNAbs to the …
ARTHUR Y KIM · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $364,178 — Project Summary Translational research is critically dependent on availability of adequate specimens from well-defined clinical cohorts of patients. This Clinical Core builds and maintains such cohorts and facilitates a broad array of studies in human immunology. During the past three cycles of our …